standard homeopathic

stress, stearine, spirulina, Stress relief, sprained ankle treatment, stress medicine, Standard Process Vitamins, Stress and Nutrition, st. johns wort, standard homeopathic, stress reducer, stress reducers, stress release, stress releif, stress reliever, stress relievers, stress relieving technique, stress relieving techniques, stress managment, stress reduction, stress management, stress management techniques, spectra, Spectra Calcium Citrate, Spectra Probiotic, spectra throat lozenges, Spectrient, Spectrient no Iron, Spectrient supplement, Spectrient supplements, Spectrient vitamin, Spectrient vitamins, Spectrient with Iron, Spectrient without Iron, st johns wort depression, st. johns wort complex, stabilium, stamina support, stinging nettle, stress support

All of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% homeopathic to 70%, while the placebo controls reported either no change or a worsening standard of symptoms. Wilcoxon-Rank of .002 for the end-points of sneezing, nasal congestion and runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged the safety of the treatment. The panel seemed to be in agreement that the statistics indicated a significant reduction in IgE and that a quantitative drop in symptoms was demonstrated. In 1992, Belen Anibarro, MD, studied five children with asthma with metabisulfite intolerance confirmed by oral challenge testing. The test was repeated after premedication with 1.5 mg of oral cyanocobalamin. In four homeopathic of the five patients treated, bronchospasm did not develop in the second metabisulfite challenge.6

All of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% homeopathic to 70%, while the placebo controls reported either no change or a worsening standard of symptoms. Wilcoxon-Rank of .002 for the end-points of sneezing, nasal congestion and runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged the safety of the treatment. The panel seemed to be in agreement that the statistics indicated a significant reduction in IgE and that a quantitative drop in symptoms was demonstrated. In 1992, Belen Anibarro, MD, studied five children with asthma with metabisulfite intolerance confirmed by oral challenge testing. The test was repeated after premedication with 1.5 mg of oral cyanocobalamin. In four homeopathic of the five patients treated, bronchospasm did not develop in the second metabisulfite challenge.6

©2003 www.specified-ailments-treatments.com. All rights reserved.